Law360, New York (October 01, 2009) -- A federal court has dismissed a consolidated putative securities class action against Pozen Inc. over disclosures made while the pharmaceutical company was seeking approval from the U.S. Food and Drug Administration for migraine treatment Treximet.
In a ruling issued Tuesday, Judge N. Carlton Tilley of the U.S. District Court for the Middle District of North Carolina agreed with a magistrate judge's recommendations that the case...
